Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chemiluminescence Immunoassay Market by Product, Technology, Sample Type, Application, End User - Global Forecast to 2031

globenewswire.com
ABT Abbott Laboratories is mentioned as a key player in the growing Chemiluminescence Immunoassay (CLIA) market. The article highlights the overall market growth driven by demand for diagnostic tests, with CLIA technology playing a vital role. Abbott's involvement suggests potential benefit from this market expansion. DHR Danaher Corporation is identified as a key player in the expanding Chemiluminescence Immunoassay (CLIA) market. The article forecasts significant growth for the CLIA market, driven by demand for diagnostic tests. Danaher's participation indicates potential for growth within this sector.

Chemiluminescence Immunoassay Market by Product, Technology, Sample Type, Application, End User - Global Forecast to 2031 Dublin, June 09, 2026 (GLOBE NEWSWIRE) -- The "Chemiluminescence Immunoassay Market by Product, Technology, Sample Type, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The chemiluminescence immunoassay (CLIA) market is expected to grow from USD 11.58 billion in 2026 to USD 16.39 billion by 2031, representing a CAGR of 7.2% from 2026 to 2031. This growth is driven by a global demand for precise diagnostic tests for chronic and infectious diseases, such as cancer, cardiovascular, thyroid disorders, and viral infections. Increasing interest in early disease detection, coupled with preventive healthcare trends, boosts the adoption of CLIA due to its high sensitivity and broad testing capabilities.

The advent of automated high-throughput testing systems has enhanced laboratory productivity. These systems reduce testing time while maintaining accuracy, benefiting from improved healthcare facilities, expanded laboratory networks, and increased medical spending in emerging markets. The rising significance of biomarker testing for personalized medicine and clinical research, combined with stringent blood screening regulations and health checkup awareness, amplifies the demand for CLIA systems globally, particularly in hospitals and reference laboratories.

In terms of products, the consumables segment is anticipated to witness the highest CAGR in the CLIA market. This segment's growth is due to the continual need for reagents, calibrators, and controls in laboratories. Consumables, such as assay kits, are in high demand for various tests, including infectious diseases, oncology markers, cardiac biomarkers, endocrine disorders, and drug monitoring. Unlike analyzers, consumables require constant replenishment, generating ongoing revenue. Technological advancements that improve reagent stability, product longevity, and operational efficiency further fuel this segment's expansion.

Regarding applications, the oncology segment is projected to grow the highest in the CLIA market. The prevalence of cancer globally heightens the need for early diagnosis and treatment monitoring, where CLIA technology proves vital due to its precise detection of tumor markers. The push for biomarker testing and precision oncology enhances the value of reliable immunoassays for targeted therapy and individualized treatment plans. Continued improvements in assay systems reinforce the adoption of CLIA in cancer diagnostics.

By end user, the hospital segment is anticipated to grow at the highest CAGR. Hospitals rely on CLIA systems for accurate diagnostics in areas such as cardiac markers and infectious pathogens. The shift towards centralized diagnostics and automation supports hospitals in reducing manual workloads while achieving standardized results. The global expansion of CLIA in hospitals is propelled by facility expansion, preventive health programs, and stringent quality standards.

The Asia Pacific region (APAC) is poised to register the highest CAGR during the forecast period. APAC's CLIA market expansion is due to enhanced healthcare systems, increasing healthcare investments, and improved diagnostic service distribution in countries like China and India. Rising chronic and infectious disease incidences, coupled with government initiatives for healthcare modernization, further accelerate CLIA system adoption. The demand for advanced immunoassay technology grows due to heightened preventive care awareness and expanded diagnostic networks, complemented by market shifts towards automation and efficiency.

Key players in the CLIA marketinclude F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Danaher Corporation, DiaSorin S.p.A., QuidelOrtho Corporation, Sysmex Corporation, and several others spanning the US, Europe, and Asia. Each company contributes significantly to market advancements with diverse product offerings and strategies.

Research Coverage:The report evaluates the CLIA market, estimating its size and growth through various segments like product, application, and end user. It includes a product portfolio matrix and competitive analysis of key market players.

Reasons to Buy the Report:This report aids market leaders and new entrants to understand the CLIA market dynamics, including revenue estimations and competitive landscapes, enabling strategic planning and positioning.

This report provides insights into the following pointers:

Key Attributes:

Key Topics Covered:

Market Dynamics

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/15fvls

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment